阿托伐他汀联合曲美他嗪治疗冠心病患者对临床疗效及相关时间指标分析

Analysis of Clinical Efficacy and Related Time Indicators of Atorvastatin Combined with Trimetazidine in Patients with Coronary Heart Disease

目的分析冠心病者应用阿托伐他汀和曲美他嗪联合医治的临床疗效、相关时间指标。方法方便选取该院2015年5月—2018年5月诊治冠心病108例患者临床资料加以分析,且依据不同医治方法分为2组,将行曲美他嗪单纯医治54例患者作为对照组,将联合阿托伐他汀医治54例患者作为研究组,比较2组临床疗效、相关时间指标和心功能。结果研究组总有效概率96.30%比对照组79.63%高(χ~2=7.083 4,P<0.05);研究组ST段下移1 mm时间(450.60±50.48)s、诱发心绞痛的发作时间(460.58±52.44)s和运动持续的时间(621.84±117.68)s均比对照组长,且左室舒张末期内径(59.20±2.11)mm、左室射血分数(47.42±10.30)%等心功能指标均比对照组优(t=5.001 7、4.337 1、3.226 1、9.545 2、5.253 5,P<0.05)。结论冠心病者应用阿托伐他汀和曲美他嗪联合医治可提高疗效,延长相关时间指标,且有利于改善患者心功能,值得推广。

Objective To analyze the clinical efficacy and related time indicators of atorvastatin combined with trimetazidine in patients with coronary heart disease. Methods The clinical data of 108 patients with coronary heart disease from May 2015 to May 2018 were convenient selected and analyzed. According to different treatment methods, the patients were divided into two groups. 54 patients who were treated with line of metopazine alone were used as the control group. 54 patients were treated with atorvastatin as the study group, and the clinical efficacy, related time indicators and cardiac function of the two groups were compared. Results The total effective probability of the study group was 96.30% higher than that of the control group （X^2=7.0834,P〈0.05）. The ST segment of the study group was moved down 1 mm （450.60±50.48） s, and the onset time of angina pectoris （460.58±52.44） s, the duration of exercise （621.84±117.68） was longer than that of the control group, and the left ventricular end-diastolic diameter （59.20±2.11） mm and left ventricular ejection fraction （47.42± 10.30）% were better than the control group（t=5.001 7, 4.337 1, 3.226 1,9.545 2,5.253 5,P〈0.05）. Conclusion The combination of atorvastatin and trimetazidine in coronary heart disease can improve the curative effect, prolong the related time index, and improve the heart function of patients. It is worthy of promotion.